Glucotrack, Inc. Announces Closing of $10.0 Million Public Offering and Concurrent Private Placement Converting $4.0 in Outstanding Debt

Core Viewpoint - Glucotrack, Inc. successfully closed a public offering, raising approximately $10 million to support its operations and development of diabetes-related technologies [1][2]. Group 1: Public Offering Details - The public offering included 2,437,340 shares of common stock and 4,756,900 pre-funded warrants, with each share and warrant accompanied by series A and series B common warrants priced at$1.81 per share [1]. - The combined offering price for each share of common stock with accompanying warrants was $1.39, while the price for each pre-funded warrant was$1.389 [1]. - Dawson James Securities, Inc. acted as the sole placement agent for the public offering, which was registered under Form S-1 and declared effective by the SEC on November 12, 2024 [2]. Group 2: Private Placement - Concurrently with the public offering, Glucotrack closed a private placement that converted approximately $4.0 million in outstanding secured convertible notes into equity on similar terms as the public offering [4]. Group 3: Company Overview - Glucotrack, Inc. focuses on designing, developing, and commercializing innovative technologies for diabetes management, including a long-term implantable continuous blood glucose monitoring system [6][7].